Related Experiment Video
Updated: Apr 27, 2026
10:14
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
4.1K
Prevalence of generalized retinal dystrophy in Denmark
Mette Bertelsen1, Hanne Jensen, Jesper F Bregnhøj
1Kennedy Center Eye Clinic, Glostrup Hospital , Glostrup , Denmark .
Ophthalmic Epidemiology
|June 26, 2014
Summary
The prevalence of generalized retinal dystrophy in Denmark is 1:3,454. This epidemiological data is crucial for understanding the disease burden and future treatment needs for generalized retinal dystrophy.
Area of Science:
- Ophthalmology
- Genetics
- Epidemiology
Background:
- Generalized retinal dystrophy is a significant cause of vision loss in young individuals.
- Few population-based epidemiological studies exist for generalized retinal dystrophy.
- Clinical intervention trials are emerging for this condition.
Purpose of the Study:
- To determine the prevalence of generalized retinal dystrophy in Denmark.
- To analyze the diagnostic spectrum of generalized retinal dystrophy within the Danish population.
Main Methods:
- A population-based cross-sectional study was conducted.
- Data were sourced from the Danish Retinitis Pigmentosa Registry (19th century to present).
- Diagnosis of generalized retinal dystrophy was confirmed via chart review, fundus photography, and electroretinograms.
Main Results:
- The prevalence of generalized retinal dystrophy in Denmark was found to be 1:3,454 (1622 patients out of 5,602,628 citizens).
- In 28% of cases, the retinal dystrophy was part of a broader syndrome; 72% involved only the eyes.
- The most common inheritance patterns were simplex (45%) and autosomal recessive (23%).
Conclusions:
- This study establishes the prevalence of generalized retinal dystrophy in the Danish population.
- Nation-wide epidemiological data are essential for assessing disease burden and planning future treatments.
- Understanding prevalence and patterns aids in evaluating the impact of ongoing clinical intervention trials.
